.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
.
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
.
. it also provides 85 per cent accurate prediction results than current methods.
.
.
.